Glioblastomas are the most frequent and aggressive primary brain tumors which are expressing various evolutions, aggressiveness, and prognosis. Thus, the 2007 World Health Organization classification based solely on the histological criteria is no longer sufficient. It should be complemented by molecular analysis for a true histomolecular classification. The new 2016 WHO classification of tumors of the central nervous system uses molecular parameters in addition to histology to reclassify these tumors and reduce the interobserver variability. The aim of this study is to determine the prevalence ofIDHmutations andEGFRamplifications in the population of the northeast region of Morocco and then to compare the results with other studies.Methods.IDH1codon 132 andIDH2codon 172 were directly sequenced and the amplification of exon 20 ofEGFRgene was investigated by qPCR in 65 glioblastoma tumors diagnosed at the University Hospital of Fez between 2010 and 2014.Results. The R132HIDH1mutation was observed in 8 of 65 tumor samples (12.31%). No mutation ofIDH2was detected.EGFRamplification was identified in 17 cases (26.15%).Conclusion. A systematic search of both histological and molecular markers should be requisite for a good diagnosis and a better management of glioblastomas.